Ocular Therapeutix, Inc. (OCUL) Given Consensus Rating of “Hold” by Brokerages
Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $22.20.
OCUL has been the topic of several research reports. Zacks Investment Research downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. ValuEngine downgraded Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a report on Thursday, September 21st. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, November 8th. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a report on Monday, September 25th. Finally, Guggenheim started coverage on Ocular Therapeutix in a report on Monday, October 23rd. They issued a “buy” rating and a $12.00 price target on the stock.
In other Ocular Therapeutix news, insider Daniel M. Bollag acquired 24,700 shares of the stock in a transaction dated Wednesday, December 6th. The stock was purchased at an average price of $3.93 per share, with a total value of $97,071.00. Following the transaction, the insider now directly owns 24,700 shares of the company’s stock, valued at $97,071. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Amarpreet Sawhney acquired 19,000 shares of the stock in a transaction dated Thursday, November 16th. The stock was acquired at an average cost of $5.18 per share, with a total value of $98,420.00. Following the transaction, the chairman now directly owns 696,390 shares in the company, valued at $3,607,300.20. The disclosure for this purchase can be found here. Insiders bought a total of 48,500 shares of company stock worth $214,691 over the last quarter. Company insiders own 26.10% of the company’s stock.
Ocular Therapeutix (NASDAQ:OCUL) opened at $4.15 on Monday. Ocular Therapeutix has a fifty-two week low of $3.30 and a fifty-two week high of $11.79. The company has a quick ratio of 4.78, a current ratio of 4.79 and a debt-to-equity ratio of 0.39.
Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). The company had revenue of $523.00 million for the quarter, compared to the consensus estimate of $0.52 million. Ocular Therapeutix had a negative return on equity of 126.31% and a negative net margin of 3,241.19%. Ocular Therapeutix’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the business posted ($0.39) EPS. equities analysts predict that Ocular Therapeutix will post -2.37 earnings per share for the current year.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.